| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Prolactin receptor, PRL-R, PRLR |
| Entrez GeneID | 5618 |
| WB Predicted band size | 69.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This PRLR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 147-179 amino acids from the Central region of human PRLR. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与PRLR抗体相关的研究文献概览：
---
1. **文献名称**：*Development of human prolactin receptor antagonists*
**作者**：Goffin V, et al.
**摘要**：研究团队开发了针对人PRLR的拮抗性抗体，通过阻断催乳素信号传导抑制乳腺癌细胞增殖。实验表明抗体可选择性抑制PRLR二聚化，为激素依赖性肿瘤治疗提供新策略。
---
2. **文献名称**：*A novel humanized antibody targeting prolactin receptor for breast cancer therapy*
**作者**：Trott JF, et al.
**摘要**：报道一种人源化PRLR抗体的设计与功能验证，该抗体通过抑制PRLR与配体结合，显著降低乳腺癌小鼠模型中肿瘤生长和转移，提示其潜在临床应用价值。
---
3. **文献名称**：*Structural basis of prolactin receptor activation by therapeutic antibodies*
**作者**：Broutin I, et al.
**摘要**：通过X射线晶体学解析PRLR与治疗性抗体的复合物结构，揭示抗体结合表位及激活机制，为优化靶向PRLR的抗体药物提供分子基础。
---
4. **文献名称**：*Prolactin receptor antibodies attenuate pregnancy-associated mammary carcinogenesis*
**作者**：Rouet V, et al.
**摘要**：在妊娠相关乳腺癌模型中，PRLR抗体通过阻断催乳素信号通路，显著减少肿瘤发生率和恶性程度，支持PRLR作为预防性治疗靶点。
---
以上文献涵盖抗体开发、结构机制及肿瘤治疗应用，可作为PRLR抗体研究的核心参考。
The prolactin receptor (PRLR) is a transmembrane protein belonging to the class I cytokine receptor superfamily, primarily activated by the hormone prolactin (PRL). PRLR plays a critical role in regulating physiological processes such as lactation, reproduction, metabolism, and immune function. Structurally, it consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular signaling domain. Upon PRL binding, PRLR dimerizes, activating downstream signaling pathways like JAK-STAT, MAPK, and PI3K-AKT.
PRLR antibodies are tools designed to detect, quantify, or modulate PRLR activity. They are widely used in research to study PRL/PRLR signaling in normal and pathological contexts, including breast cancer, prostate cancer, and reproductive disorders where PRLR overexpression is implicated. Therapeutic PRLR antibodies, often monoclonal, are explored for targeting PRLR-positive cancers by blocking ligand-receptor interactions or inducing receptor internalization. Diagnostic applications include immunohistochemistry to assess PRLR expression in tumor biopsies for prognostic or predictive purposes.
Antibodies vary in specificity (monoclonal vs. polyclonal) and epitope targeting (extracellular vs. intracellular domains). Challenges include minimizing cross-reactivity with related receptors (e.g., growth hormone receptor) and optimizing pharmacokinetics for therapeutic use. Recent advances focus on humanized antibodies and bispecific designs to enhance efficacy in oncology and autoimmune disease models.
×
